157 related articles for article (PubMed ID: 24987183)
1. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
Sil A; Das NK
Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183
[TBL] [Abstract][Full Text] [Related]
2. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
4. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
5. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
6. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
8. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
10. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
11. Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS; Frenette CT; Keefe SM; Stein SM
Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
14. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
16. Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Ogawa C; Morita M; Omura A; Noda T; Kubo A; Matsunaka T; Tamaki H; Shibatoge M; Tsutsui A; Senoh T; Nagano T; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kokudo Y; Minami Y; Ueshima K; Sakurai T; Nishida N; Kudo M
Oncology; 2017; 93 Suppl 1():113-119. PubMed ID: 29258090
[TBL] [Abstract][Full Text] [Related]
17. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
19. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
[TBL] [Abstract][Full Text] [Related]
20. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Walko CM; Grande C
Semin Oncol; 2014 Feb; 41 Suppl 2():S17-28. PubMed ID: 24576655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
